Enliven Therapeutics Inc. has divulged Raf kinase inhibitors reported to be useful for the treatment of cancer. An exemplified compound (Ex 5 [isomer B] pg 130) inhibited ERK phosphorylation in human melanoma A-375 cells (IC50=12.4 nM) in ELISA assays.
Researchers at De Montfort University and Loughborough University have identified trifluoroquinazolines acting as lysyl tRNA synthetase (KARS) inhibitors reported to be useful for the treatment of parasitic infections.
Rockefeller University has disclosed non-structural protein 3 (nsp3; PL-PRO) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).
Chengdu Duote Antibody Pharmaceutical Co. Ltd. has described antibody-drug conjugates comprising antibody or antigen-binding fragments covalently linked to eribulin derivatives through a linker reported to be useful for the treatment of cancer.
Nanjing Mingde New Drug Research Co. Ltd. has divulged proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase-binding agent coupled to an estrogen receptor α (ER-α; ESR1)-targeting moiety via linker. They are reported to be useful for the treatment of breast cancer.
Shenzhen Zhongge Biotechnology Co. Ltd. has identified interleukin-1 receptor-associated kinase 4 (IRAK-4) inhibitors and derived PROTAC compounds reported to be useful for the treatment of autoimmune disorders, inflammatory disorders, cancer, transplant rejection and more.
Beijing Zheyuan Technology Co. Ltd. has synthesized serine/threonine-protein kinase PLK1 (STPK13) inhibitors reported to be useful for the treatment of cancer and sepsis.
Researchers at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have described GTPase KRAS mutant inhibitors, particularly KRAS G12C mutant, reported to be useful for the treatment of cancer.
RSS